Foresee Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	854.57	1,367	1,010	689.51	871.44	1,145
Short-Term Investments	-	-	150	-	100	125
Trading Asset Securities	-	-	-	-	297.47	351.68
Cash & Short-Term Investments	854.57	1,367	1,160	689.51	1,269	1,622
Cash Growth	19.55%	17.90%	68.19%	-45.66%	-21.76%	226.86%
Accounts Receivable	71.58	32.33	65.91	16.27	-	-
Other Receivables	20.84	26.55	22.18	10.13	5.73	13.97
Receivables	92.42	58.88	88.09	26.4	5.73	13.97
Inventory	140.12	183.87	126.8	176.41	24.88	34.11
Prepaid Expenses	61.32	132.48	23.56	22.75	3.9	9.71
Other Current Assets	125	75	192.5	-	-	6.62
Total Current Assets	1,273	1,818	1,591	915.06	1,303	1,686
Property, Plant & Equipment	180.92	217.62	135.01	142.39	91.19	110.8
Other Intangible Assets	112.94	117.79	126.81	140.96	155.14	209.44
Long-Term Deferred Tax Assets	1.21	1.31	1.23	1.22	1.1	1.14
Other Long-Term Assets	4.97	4.9	7.76	104.39	90.58	92.06
Total Assets	1,573	2,159	1,861	1,304	1,641	2,100
Accounts Payable	0	64.42	12.13	22.85	-	-
Accrued Expenses	76.35	85.57	120.71	78.47	61.68	45.8
Short-Term Debt	250	150	200	-	-	30.07
Current Portion of Long-Term Debt	5	5	-	-	-	20.79
Current Portion of Leases	2.28	12.41	15.14	15.52	10.2	9.38
Current Income Taxes Payable	6.48	8.82	10.42	4.95	-	-
Current Unearned Revenue	-	50.03	105.48	1.01	0.78	1.52
Other Current Liabilities	7.01	16.97	6.96	6.38	1.79	14.03
Total Current Liabilities	347.11	393.21	470.83	129.17	74.45	121.59
Long-Term Debt	89.17	92.92	-	-	-	63.24
Long-Term Leases	-	-	13.12	25.8	6.45	6.68
Long-Term Unearned Revenue	72.62	72.62	131.67	237.15	239.17	77.67
Long-Term Deferred Tax Liabilities	1.31	1.41	1.32	1.32	1.19	1.22
Total Liabilities	510.2	560.15	616.93	393.43	321.26	270.4
Common Stock	1,575	1,548	1,358	1,182	1,179	1,169
Additional Paid-In Capital	6,086	5,906	4,617	3,424	3,372	3,319
Retained Earnings	-6,547	-5,811	-4,730	-3,693	-3,221	-2,651
Comprehensive Income & Other	-50.59	-44.56	-1.49	-1.54	-10.21	-8.06
Shareholders' Equity	1,063	1,599	1,245	910.58	1,320	1,829
Total Liabilities & Equity	1,573	2,159	1,861	1,304	1,641	2,100
Total Debt	346.44	260.33	228.26	41.32	16.65	130.15
Net Cash (Debt)	508.13	1,107	931.42	648.19	1,252	1,492
Net Cash Growth	45.04%	18.85%	43.70%	-48.24%	-16.05%	208.45%
Net Cash Per Share	3.37	8.06	7.32	5.49	10.67	14.71
Filing Date Shares Outstanding	157.54	154.79	135.82	118.17	117.94	116.94
Total Common Shares Outstanding	157.54	154.79	135.82	118.17	117.94	116.94
Working Capital	926.32	1,424	1,120	785.89	1,229	1,565
Book Value Per Share	6.75	10.33	9.16	7.71	11.19	15.64
Tangible Book Value	950.33	1,481	1,118	769.62	1,165	1,620
Tangible Book Value Per Share	6.03	9.57	8.23	6.51	9.88	13.85
Land	123.07	123.07	-	-	-	-
Buildings	9.96	9.96	-	-	-	-
Machinery	228.86	226.59	209.45	171.58	136.94	144.58
Construction In Progress	0.25	-	4.9	20.39	4.4	1.31
Leasehold Improvements	30.44	30.44	30.44	7.71	7.71	7.71

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.